Franc Gay, MD, PhD, discs the FORTE trial parg rfilzomib pl lenalidomi and xamethasone vers rfilzomib pl cyclophosphami and xamethasone newly diagnosed patients wh multiple myeloma.
Contents:
- FRANC GAY
- FRANC GAY, MD, PHD
- FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
- GAY MOSW MOSW CY GUI
- FIRG OF GAY CATHOLIC SCHOOL TEACHER ULD TT LATT SUPREME COURT LG
FRANC GAY
Franc Gay speaks exclively to VJHemOnc on Treatg myeloma and associated disorrs. Watch terviews and discsns wh Franc Gay here. * francesca gay md *
Franc Gay is Associate Profsor the Universy of Toro, Department of Molecular Btechnology and Health Scienc, and works as hematologist at the SSD Clil trials on-ematology and multiple myeloma, Divisn of Hematology, Azienda Ospedaliero-Universaria Ctà lla Salute e lla Scienza di Toro, Italy.
Gay’s ma rearch foc on the diagnosis and the clil and experimental treatment of patients wh multiple myeloma and associated disorrs, particularly of newly diagnosed patients eligible for tologo stem-cell transplantatn. Franc Gay, MD, PhD, is currently an Associate Profsor of Hematology at the Myeloma Un the Divisn of Hematology at the Universy of Tur, Tur, Italy, havg prevly worked as a Hematologist at the Azienda Ospedaliera Ctà lla Salute e lla Scienza di Toro, Tur, Italy. Dr Gay pleted her medil gree 2004 and her fellowship hematology 2008, both om the Universy of Tur.
In 2014, Dr Gay obtaed a PhD Medice and Experimental Therapy and has been a member of the young European Myeloma Network (EMN) board sce s formatn 2019. Dr Gay’s rearch is foced on the treatment of multiple myeloma and s associated diseas. Dr Gay has prevly worked on many cuttg-edge clil trials and is currently heavily volved rearch vtigatg prognostic factors, such as measurable ridual disease (MRD), multiple myeloma.
FRANC GAY, MD, PHD
* francesca gay md *
Gay et al.
FigureDisclosurGay:Amgen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Takeda: Honoraria, Membership on an enty's Board of Directors or advisory mte; Bristol-Myers Squibb: Honoraria, Membership on an enty's Board of Directors or advisory mte; Roche: Membership on an enty's Board of Directors or advisory mte; GSK: Membership on an enty's Board of Directors or advisory mte; AbbVie: Membership on an enty's Board of Directors or advisory mte; Adaptive: Membership on an enty's Board of Directors or advisory mte; Seattle Geics: Membership on an enty's Board of Directors or advisory mte; Onpeptis: Membership on an enty's Board of Directors or advisory mte; Janssen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Celgene: Honoraria, Membership on an enty's Board of Directors or advisory mte.
FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
Franc Gay, MD, PhD, discs nsolidatn as a standard of re the transplant settg * francesca gay md *
Franc Gay, MD,. Franc Gay, Chiara Cerrato, Delia Rota Slabri, Moni Galli, Angelo Belotti, Elena Zamagni, Anton Ledda, Mariella Grasso, Emanuele Angelucci, Anna Mara Liberati, Patrizia Tosi, Franc Pisani, Stefano Spada, Ombretta Annibali, Anna Baraldi, Paola Omedé, Piero Galieni, Ra Rizzi, Norbert Psta, Sonia Ronni, Donatella Vcelli, Anna Maria Cao, Massimo Offidani, Anton Palumbo, Pellegro Mto, Michele Cavo, Mar Bocdoro; Carfilzomib-Lenalidomi-Dexamethasone (KRd) Inductn-Autologo Transplant (ASCT)-Krd Consolidatn Vs KRd 12 Cycl Vs Carfilzomib-Cyclophosphami-Dexamethasone (KCd) Inductn-ASCT-KCd Consolidatn: Analysis of the Randomized Forte Trial Newly Diagnosed Multiple Myeloma (NDMM). June 28th 2018Franc Gay, MD, PhD, hematologist, Myeloma Un, Divisn of Hematology, Azienda Ospedaliero Universaria Ctà lla Salute e lla Scienza, discs the updated efficy data om the FORTE trial of patients wh newly-diagnosed multiple myeloma.
GAY MOSW MOSW CY GUI
Explore gay Mosw wh Mr Hudson. The bt of Mosw for the discerng gay man. Where to sleep, eat, drk, shop and play. * francesca gay md *
Pieter Sonneveld, Meral Beksac, Bronno Van Der Holt, Melets A Dimopoulos, Angelo Michele Carella, Hez Ludwig, Sonja Zweegman, Thilo Zanr, Ruth Wter, Roman Hajek, Lucia Pantani, Lu Dozza, Franc Gay, Anna Maria Cao, Lu De Rosa, Franc Froni, Ulf-Henrik Mellqvist, Rossella Troia, Niels Frost Anrsen, Ka Lung Wu, Christoph Drisen, Sana Carvalho, Alexandra J. Gay:GSK: Membership on an enty's Board of Directors or advisory mte; Adaptive: Membership on an enty's Board of Directors or advisory mte; AbbVie: Membership on an enty's Board of Directors or advisory mte; Roche: Membership on an enty's Board of Directors or advisory mte; Bristol-Myers Squibb: Honoraria, Membership on an enty's Board of Directors or advisory mte; Seattle Geics: Membership on an enty's Board of Directors or advisory mte; Onpeptis: Membership on an enty's Board of Directors or advisory mte; Amgen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Celgene: Honoraria, Membership on an enty's Board of Directors or advisory mte; Janssen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Takeda: Honoraria, Membership on an enty's Board of Directors or advisory mte.
Franc Gay, MD, of GIMEMA, European Myeloma Network, discs the potential role of rfilzomib/lenalidomi/xamethasone wh or whout transplantatn ducg high-qualy rpons, achievg negative mimal ridual disease, and rcg the risk of early relapse.
Franc Gay, MD, PhD, discs the FORTE trial parg rfilzomib pl lenalidomi and xamethasone vers rfilzomib pl cyclophosphami and xamethasone newly diagnosed patients wh multiple myeloma. Franc Gay, MD, PhD, associate profsor of onlogy and urology at Johns Hopks MediceFranc Gay, MD, PhDThe batn of rfilzomib (Kyprolis), lenalidomi (Revlimid), and xamethasone (KRd) may reprent a new standard of re for patients wh newly diagnosed multiple myeloma, cludg those wh high-risk disease, said Franc Gay, MD,, a hematologist the Myeloma Un, Divisn of Hematology, Azienda Ospedaliero Universaria Ctà lla Salute e lla Scienza, prented updated efficy rults om the FORTE trial at the 2018 European Hematology Associatn Congrs.
FIRG OF GAY CATHOLIC SCHOOL TEACHER ULD TT LATT SUPREME COURT LG
Gay add that KRd was associated wh better rults across all subgroups. In an terview wh OncLive®, Gay reviewed the rults of the FORTE trial and discsed how cludg MRD asssment and risk stat n make clil trials more valuable for We saw that, by an tent-to-treat analysis, the rate of PR after ductn was very high both arms at around 90%. Gay F, D'Agosto M, Giacne L, et al.
[Crossref] [PubMed]Ce this article as: Bertami L, Gay F.